Sei Investments CO Alnylam Pharmaceuticals, Inc. Transaction History

Sei Investments CO

$66.7 Billion
Q1 2024

A detailed history of Sei Investments CO transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Sei Investments CO holds 29,603 shares of ALNY stock, worth $7.33 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

29,603

Previous 26,249 12.78%

Holding current value

$7.33 Million

Previous $5.02 Million 11.94%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$146.51 - $198.2 $491,394 - $664,762	3,354 Added 12.78%	29,603 $4.42 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $143,385 - $186,151	947 Added 3.74%	26,249 $5.02 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $761,804 - $944,170	-4,461 Reduced 14.99%	25,302 $4.48 Million
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $457,529 - $524,399	2,473 Added 9.06%	29,763 $5.65 Million
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $62,469 - $80,551	-342 Reduced 1.24%	27,290 $5.47 Million

Q4 2022 Feb 10, 2023	SELL	$185.53 - $241.31 $136,735 - $177,845	-737 Reduced 2.6%	27,632 $6.57 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $290,102 - $485,808	2,094 Added 7.97%	28,369 $5.68 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $260,950 - $366,851	-2,167 Reduced 7.62%	26,275 $3.77 Million
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $381,667 - $521,903	3,001 Added 11.8%	28,442 $4.59 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $220,033 - $288,610	1,379 Added 5.73%	25,441 $4.42 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $38,872 - $47,570	229 Added 0.96%	24,062 $4.61 Million
Q2 2021 Aug 06, 2021	BUY	$128.63 - $176.89 $594,013 - $816,878	4,618 Added 24.03%	23,833 $4.12 Million
Q1 2021 May 12, 2021	SELL	$126.83 - $175.69 $317,075 - $439,225	-2,500 Reduced 11.51%	19,215 $2.72 Million
Q4 2020 Feb 08, 2021	SELL	$122.97 - $147.0 $160,106 - $191,394	-1,302 Reduced 5.66%	21,715 $2.86 Million
Q3 2020 Dec 04, 2020	SELL	$121.19 - $165.49 $315,094 - $430,274	-2,600 Reduced 10.15%	23,017 $3.36 Million
Q3 2020 Nov 06, 2020	SELL	$121.19 - $165.49 $600,860 - $820,499	-4,958 Reduced 16.22%	25,617 $3.74 Million
Q2 2020 Aug 17, 2020	SELL	$104.21 - $156.44 $294,497 - $442,099	-2,826 Reduced 8.46%	30,575 $4.53 Million
Q2 2020 Aug 11, 2020	BUY	$104.21 - $156.44 $405,585 - $608,864	3,892 Added 13.19%	33,401 $3.98 Million
Q1 2020 May 14, 2020	SELL	$93.12 - $133.99 $63,135 - $90,845	-678 Reduced 2.25%	29,509 $3.21 Million
Q4 2019 Feb 06, 2020	SELL	$74.51 - $124.23 $3.47 Million - $5.79 Million	-46,616 Reduced 60.7%	30,187 $3.47 Million
Q3 2019 Nov 12, 2019	BUY	$70.9 - $87.82 $66,220 - $82,023	934 Added 1.23%	76,803 $6.13 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $1.34 Million - $1.88 Million	20,283 Added 36.49%	75,869 $5.48 Million
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $959,849 - $1.23 Million	13,192 Added 31.12%	55,586 $5.18 Million
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $18,424 - $25,969	294 Added 0.7%	42,394 $3.69 Million
Q3 2018 Nov 08, 2018	SELL	$87.52 - $122.67 $1.78 Million - $2.49 Million	-20,328 Reduced 32.56%	42,100 $3.68 Million
Q2 2018 Aug 03, 2018	BUY	$88.31 - $107.8 $2.65 Million - $3.23 Million	30,006 Added 92.55%	62,428 $6.15 Million
Q1 2018 May 11, 2018	SELL	$115.92 - $148.54 $1.94 Million - $2.49 Million	-16,754 Reduced 34.07%	32,422 $3.86 Million
Q4 2017 Feb 08, 2018	SELL	$114.49 - $139.98 $112,200 - $137,180	-980 Reduced 1.95%	49,176 $6.25 Million
Q3 2017 Nov 06, 2017	BUY	$72.53 - $118.27 $3.64 Million - $5.93 Million	50,156	50,156 $5.89 Million

Others Institutions Holding ALNY

# of Institutions

585

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.5B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account

Sei Investments CO Alnylam Pharmaceuticals, Inc. Transaction History